ALS Untangled does not recommend low-dose naltrexone for ALS
Original source
Low dose naltrexone for ALS (opens in a new tab)ALS Untangled said it does not recommend low-dose naltrexone (LDN) for people with ALS. It found no convincing evidence of benefit and noted that reported benefits from a small PatientsLikeMe group were inconsistent and not objectively verified. The review said further pharmacological studies are needed and raised possible side effects, including liver toxicity.
Why this matters
This assessment does not support using LDN as an ALS treatment. People considering it should know that the available evidence reviewed was limited and did not show an objective benefit.
Limitations and context
This is an independent expert review published in 2010, not a new clinical trial. It reports limited observational information and a small pilot study of a drug with similar mechanisms; the review says further studies are needed to clarify LDN’s effects and risks.